Pharmaids (PHARMAID) | Financial Analysis & Statements
Pharmaids Pharmaceuticals Limited Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
54.3M
Gross Profit
30.8M
56.76%
Operating Income
-29.8M
-54.88%
Net Income
-26.5M
-48.73%
EPS (Diluted)
₹-0.70
Balance Sheet Metrics
Total Assets
984.4M
Total Liabilities
471.3M
Shareholders Equity
513.1M
Debt to Equity
0.92
Cash Flow Metrics
Operating Cash Flow
-1.1M
Free Cash Flow
2.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Pharmaids Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 188.1M | 146.0M | 0 | 39.4M | 85.5M |
| Cost of Goods Sold | 142.7M | 129.0M | 8.9M | 35.7M | 81.6M |
| Gross Profit | 45.4M | 17.0M | -8.9M | 3.7M | 3.9M |
| Gross Margin % | 24.1% | 11.6% | 0.0% | 9.3% | 4.6% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 12.1M | 13.9M | 2.1M | 609.6K | 418.7K |
| Other Operating Expenses | 24.0M | 34.3M | 74.8M | 533.4K | 1.0M |
| Total Operating Expenses | 36.1M | 48.2M | 76.9M | 1.1M | 1.5M |
| Operating Income | -151.6M | -140.1M | -99.0M | 1.3M | 732.0K |
| Operating Margin % | -80.6% | -95.9% | 0.0% | 3.2% | 0.9% |
| Non-Operating Items | |||||
| Interest Income | 935.0K | 2.2M | 0 | - | - |
| Interest Expense | 20.1M | 15.4M | 0 | 0 | 0 |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -172.8M | -156.2M | -99.1M | 1.4M | 884.3K |
| Income Tax | -37.7M | -37.8M | -23.5M | -48.8K | -48.8K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | -3.5% | -5.5% |
| Net Income | -135.1M | -118.4M | -75.6M | 1.5M | 933.1K |
| Net Margin % | -71.8% | -81.1% | 0.0% | 3.7% | 1.1% |
| Key Metrics | |||||
| EBITDA | -127.3M | -115.0M | -98.9M | 1.4M | 1.4M |
| EPS (Basic) | ₹-3.06 | ₹-3.51 | ₹-5.86 | ₹0.14 | ₹0.09 |
| EPS (Diluted) | ₹-3.06 | ₹-3.51 | ₹-5.86 | ₹0.14 | ₹0.09 |
| Basic Shares Outstanding | 35267812 | 22718464 | 12896166 | 10311234 | 10311234 |
| Diluted Shares Outstanding | 35267812 | 22718464 | 12896166 | 10311234 | 10311234 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Pharmaids Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 21.4M | 48.0M | 127.5M | 4.1M | 2.0M |
| Short-term Investments | - | - | 33.1M | - | - |
| Accounts Receivable | 31.3M | 26.8M | 20.5M | 13.4M | 2.8M |
| Inventory | 121.8M | 35.9M | 0 | 8.9M | 3.7M |
| Other Current Assets | 48.5M | -1.0K | 1.0K | 339.0K | 106.0K |
| Total Current Assets | 223.1M | 135.3M | 183.2M | 26.7M | 8.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 19.3M | 10.7M | 1.1M | 4.2M | 4.2M |
| Goodwill | 633.8M | 633.8M | 0 | - | - |
| Intangible Assets | 5.5M | 5.5M | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.0K | -1.0K | 1.2M | - | - |
| Total Non-Current Assets | 975.5M | 778.1M | 62.7M | 84.4M | 82.6M |
| Total Assets | 1.2B | 913.4M | 245.8M | 111.1M | 91.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 163.2M | 51.2M | 18.8M | 23.1M | 5.0M |
| Short-term Debt | 58.6M | 24.8M | 0 | 0 | 0 |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 8.4M | 614.0K | 472.0K | 1.3M | 869.0K |
| Total Current Liabilities | 287.1M | 115.8M | 21.2M | 24.4M | 5.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 331.2M | 60.5M | 0 | 0 | 0 |
| Deferred Tax Liabilities | - | - | 0 | 0 | 0 |
| Other Non-Current Liabilities | -1.0K | -1.0K | -1.0K | - | - |
| Total Non-Current Liabilities | 361.0M | 92.7M | -1.0K | 0 | 0 |
| Total Liabilities | 648.1M | 208.4M | 21.2M | 24.4M | 5.9M |
| Equity | |||||
| Common Stock | 352.7M | 352.7M | 214.4M | 102.7M | 102.7M |
| Retained Earnings | -266.8M | -139.3M | -98.9M | -23.3M | -24.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 550.4M | 705.0M | 224.6M | 86.7M | 85.3M |
| Key Metrics | |||||
| Total Debt | 389.7M | 85.3M | 0 | 0 | 0 |
| Working Capital | -64.1M | 19.6M | 161.9M | 2.3M | 2.7M |
Balance Sheet Composition
Pharmaids Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -172.8M | -156.2M | -99.1M | 1.4M | 884.3K |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -125.6M | 17.2M | 62.6M | -2.6M | -2.2M |
| Operating Cash Flow | -278.1M | -131.9M | -36.4M | -1.2M | -1.3M |
| Investing Activities | |||||
| Capital Expenditures | -122.6M | -227.2M | -16.7M | 0 | -15.0K |
| Acquisitions | 0 | -524.8M | -32.7M | - | - |
| Investment Purchases | - | - | -32.7M | - | 0 |
| Investment Sales | - | - | - | - | 0 |
| Investing Cash Flow | -122.6M | -752.0M | -82.1M | 4.7M | 4.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 327.0M | 15.3M | 0 | - | 0 |
| Debt Repayment | -49.1M | -18.0M | 0 | - | 0 |
| Financing Cash Flow | 258.2M | 795.6M | 213.1M | 0 | 0 |
| Free Cash Flow | -264.7M | -334.8M | -56.9M | -2.6M | 4.0M |
| Net Change in Cash | -142.6M | -88.3M | 94.6M | 3.5M | 3.2M |
Cash Flow Trend
Pharmaids Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
2,023.33
Price to Book
2.11
Price to Sales
4.28
PEG Ratio
74.19
Profitability Ratios
Profit Margin
-54.23%
Operating Margin
-54.88%
Return on Equity
-19.58%
Return on Assets
-8.99%
Financial Health
Current Ratio
0.81
Debt to Equity
39.24
Beta
0.06
Per Share Data
EPS (TTM)
₹-5.13
Book Value per Share
₹14.65
Revenue per Share
₹7.21
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PHARMAID | 1.1B | 2,023.33 | 2.11 | -19.58% | -54.23% | 39.24 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





